Crinetics' Palsonify Launch Hits Its Stride: 232 New Patients, 70% Reimbursed, and a Pipeline Still Building

Q1 2026 results show the acromegaly launch is compounding, with revenue scaling, reimbursement climbing, and international approval adding optionality.

CRNX · Earnings Call · 2026-05-08

A Launch That Is Compounding

Crinetics' first full quarter of commercial Palsonify sales delivered a clear inflection. The company secured 232 new patient enrollment forms in Q1, up from 200 in the prior quarter, while net product revenue reached $10.3 million. More striking is the shift in patient mix: treatment-naive patients swelled from 5% of enrollments in Q4 to 15% in Q1, a sign that physician confidence is broadening beyond early adopters. As CEO Scott Struthers put it, “This collective effort has translated into 232 additional patient enrollments and $10.3 million in net product revenue for the quarter.” — R. Struthers, Founder and Chief Executive Officer · 2026-05-08 The momentum is also visible in the stock's tape: CRNX surged 128% in nine days after the report, and the last 90 days show a +114.7% return. The market is voting that this is not just a one-off spike but a durable commercial trajectory. naive patient growth and new standard positioning are becoming core to the narrative, and the company is leaning into that with real-world evidence and educational campaigns. Isabel Kalofonos, Chief Commercial Officer, emphasized the breadth: “we are very pleased that 70% of the total systems and the patients are getting reimbursed” — Isabel Kalofonos, Chief Commercial Officer · 2026-05-08—a jump from 50% just a quarter earlier.

Payer Wins and the Road to 75%

Reimbursement is the foundation of any rare-disease launch, and here Crinetics is ahead of schedule. The company achieved over 60% coverage and remains on track to exceed its 75% goal by Q3 2026. Management attributes this to the drug's differentiated profile—rapid onset, once-daily oral dosing, and superior efficacy data. The payer discussions are translating into formulary wins earlier than typical decision timelines. strength of Palsonify is resonating across the market, and the company's access team is converting Quick Start patients to reimbursed drug at a steady pace. The operational efficiency here matters. In the prior quarter, the Quick Start program was still a major bridge, with 50% of patients starting on free drug. Now, that proportion has dropped to roughly 30%, and the company expects nearly all patients to eventually convert to paid therapy. “What we're really pleased to say right now is that at the initial point of kind of measurement, about 50% of patients are reimbursed for commercial or Medicare and Medicaid and the other 50% go on to that Quickstart program.” — Tobin Schilke, Chief Financial Officer · 2026-02-26 The progress since then is a tangible sign of execution.

Pipeline and Global Expansion: The Next Acts

Beyond the launch, Crinetics is advancing a deep pipeline that could dwarf the acromegaly opportunity. The Phase III CAH program for atumelnant is actively enrolling, with a pediatric study now initiated, and the company plans interim OLE data later this year. The 9682 program—a peptide-drug conjugate for SST2-expressing tumors—is in dose escalation, with expansion cohorts already mapped out. Management is also expanding internationally: the European Commission approved the MAA for Palsonify, a Japanese submission is underway, and a Brazilian filing has been completed. Scott Struthers framed the broader ambition:

Palsonify sets a new standard of care for the treatment of acromegaly and is on track to become the most prescribed brand.
R. Struthers, Founder and Chief Executive Officer · 2026-05-08

He added that the company is “building a premier endocrinology company,” not just executing a single launch. early adopters is giving way to healthcare providers across community and academic centers, and the pipeline is being funded by the commercial engine.

Cash, Costs, and the Long Runway

Financially, the story is one of deliberate investment. Total revenue surged to $10.7 million in Q1, a 74% sequential increase, while R&D expenses rose to $100 million as the Phase III trials ramp up. The balance sheet remains fortress-like: Total Revenue is up 2,873% year-over-year, but operating income is still deeply negative at -$140 million. Yet the company ended the quarter with $1.3 billion in cash, enough to fund operations into 2030. “we project that our existing cash and investments will be sufficient to fund our operations into 2030.” — Tobin Schilke, Chief Financial Officer · 2026-05-08 The launch is now the primary catalyst, but the pipeline is the long-term value driver. With positive momentum on all fronts—revenue growth, payer coverage, patient enrollment, and clinical development—Crinetics is transitioning from a development-stage biotech to a commercial-stage company with multiple shots on goal. The tape is reflecting that transition, and the fundamentals are confirming it, albeit from a small base. The next few quarters will show whether this compound growth continues to meet the market's high expectations.